Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-181 pembrolizumab versus chemotherapy in previously treated advanced esophageal cancer
NL-OMON45950Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in esophageal cancer, esophageal adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC) and 1 more, sponsored by Merck & Co. Primary endpoints: Overall Survival in esophageal squamous cell carcinoma, Overall Survival in PD-L1 CPS >=10 population and 1 more. Started Dec 2015; status: active, not recruiting.
02
Drugs
03
Conditions
esophageal canceresophageal adenocarcinoma (EAC)Esophageal Squamous Cell Carcinoma (ESCC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON45950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45950.